Recent advances, prospects and problems in designing new strategies for oligonucleotide and gene delivery in therapy

In Vivo

Volumn 12, Issue 1, 1998, Pages 59-67

  Romano, Gaetano ^a   Claudio, Pier Paolo ^b   Kaiser, Hans E ^c,d   Giordano, Antonio ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF VIENNA   (Austria)

Author keywords

Adeno associated virus; Adenovirus; Cationic liposomes; Clinical trials; Gene delivery systems in vivo or in vitro; Gene therapy; Retroviruses

Indexed keywords

LIPOSOME; OLIGONUCLEOTIDE;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ARTICLE; EXPRESSION VECTOR; GENE TARGETING; GENE THERAPY; GENETIC DISORDER; HUMAN; NONHUMAN; RETROVIRUS;

EID: 0031966023     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (136)

1. Molecular and Cellular Biology of Gene Therapy, April 13-19, 1997, Snowbird, Utah, USA.
2. Wolff JA, Lederberg J: An early history of gene transfer and therapy. Hum Gene Ther 5: 469-480, 1994.
3. Culver KW, Osborne WR, Miller AD, Fleisher TA, Berger M, Anderson WF, Blaese RM: Correction of ADA deficiency in human T lymphocytes using retroviral-mediated gene transfer. Transplant Proc 23: 170-171, 1991.
4. Anderson, WF: End-of-the-year potpourri-1995. Hum Gene Ther 6: 1505-1506, 1995.
5. Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL, et al: Gene transfer into humans: immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med 323: 570-578, 1990.
6. Osanto S, Brouwenstyn N, Vaessen N, Figdor CG, Melief CJ, Schrier PI: Immunizazion with interleukin-2 transfected melanoma cells. A phase I-II study in patients with metastatic melanoma. Hum Gene Ther 4: 323-330, 1993.
7. Arienti F, Sule-Suso J, Belli F, Mascheroni L, Rivoltini L, Melani C, Maio M, Cascinelli N, Colombo MP, Parmiani G: Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogenic melanoma cells. Hum Gene Ther 7: 1955-1963, 1996.
8. Nabel GJ, Gordon D, Bishop DK, Nickoloff BJ, Yang ZY, Aruga A, Cameron MJ, Nabel EG, Chang AE: Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci USA 93: 15388-15393, 1996.
9. Klatzman D: Gene therapy for metastatic malignant melanoma: evaluation of tollerance to intratumoral injection of cells producing recombinant retroviruses carrying the herpes simplex virus type 1 thymidine kinase gene, to be followed by ganciclovir administration. Hum Gene Ther 7: 255-267, 1996.
10. Stopeck AT, Hersh EM, Akporiaye ET, Harris DT, Grogan T, Unger E, Warneke J, Schluter SF, Stahl S: Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. J Clin Oncol 15: 341-349, 1997.
11. Mahvi DM, Sondel PM, Yang NS, Albertini MR, Schiller JH, Hank J, Heiner J, Gan J, Swain W, Logrono R: Phase I/IB study of immunization with autologous tumor cells transduced with the GM-CSF gene by particle-mediated transfer in patients with melanoma or sarcoma. Hum Gene Ther 8: 875-891, 1997.
12. Deshane J, Siegal GP, Wang M, Wright M, Bucy RP, Alvarez RD, Curiel DT: Transductional efficiency and safety of an intraperitoneally delivered adenovirus encoding an anti-erbB intracellular single-chain antibody for ovarian cancer therapy. Gynecol Oncol 64: 378-385, 1997.
13. Xing X, Liu V, Xia W, Stephens LC, Huang L, Lopez-Berenstein G, Hung MC: Safety studies of the intraperitoneal injection of Ela-liposome complex in mice. Gene Ther 4: 238-243, 1997.
14. Kun LE, Gajjar A, Muhlbauer M, Heideman RL, Sanford R, Brenner M, Walter A, Langston J, Jenkins J, Facchini S: Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA 317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors. Hum Gene Ther 6: 1231-1255, 1995.
15. Nguyen DM, Spitz FR, Yen N, Cristiano RJ, Roth JA: Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systematic cisplatin and adenovirus-mediated p53 gene transfer. J Thorac Cardiovasc Surg 112: 1372-1376, 1996.
16. Cournoyer D, Caskey CT: Gene therapy of the immune system. Annu Rev Immunol 11: 297-329, 1993.
17. Gilboa E: Retroviral gene transfer: applications to human gene therapy. Prog Clin Biol Res 352: 301-311, 1990.
18. Kohn DB, Anderson WF, Blaese MB: Gene therapy for genetic diseases. Cancer Invest 7: 179-192, 1989.
19. Miller AD: Retrovirus packaging cells. Hum Gene Ther 1: 5-14.
20. Temin HM: Retrovirus vectors for gene transfer: efficient integration into and expressionof exogenous DNA in vertebrate cell genomes. In: Gene Transfer (Kucherlapati R, ed). New York, Plenum Press. 1986. pp 144-187.
21. Blacklow NR, Hoggan MD, Kapikian AZ, Austin JB, Rowe WP: Epidemiology of adenovirus-associated virus infection in a nursery population. Am J Epidemiol 88: 368-378, 1968.
22. Berns KI, Pinkerton TC, Thomas GF, Hoggan MD: Detection of adeno-associated virus (AAV)-specific nucleotide sequences in DNA isolated from latently infected Detroit 6 cells. Virology 68: 556-560, 1975.
23. Cheung AK, Hoggan MD, Hauswirth WW, Berns KI: Integration of the adeno-associated virus genome into cellular DNA in latently infected human Detroit 6 cells. J Virol 33: 739-748, 1980.
24. Podsakoff G, Wong KK Jr, Chatterjee S: Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. J Virol 68: 5656-5666, 1994.
25. Kotin RM, Berns KI: Organization of adeno-associated virus DNA in latently infected Detroit 6 cells. Virology 170: 460-467, 1989.
26. Kotin RM, Siniscalco M, Samulski RJ, Zhu XD, Hunter L, Laughlin CA, McLaughlin S, Muzyczka N, Rocchi M, Berns KI: Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 87: 2211-2215, 1990.
27. Kotin RM, Linden RM, Berns KI: Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J 11: 5071-5078, 1992.
28. Kotin RM, Menninger JC, Ward DC, Berns KI: Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter. Genomics 10: 831-834, 1991.
29. Samulski RJ, Zhu X, Xiao X, Brook JD, Housman DE, Epstein N, Hunter LA: Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 10: 3941-3950, 1991.
30. Russell DW, Miller AD, Alexander IE: Adeno-associated virus vectors preferentially transduce cells in S phase. Proc Natl Acad Sci USA 91: 8915-8919, 1994.
31. Rowe WP, Huebner RJ, Gilmore LK, Parrot RH, Ward TG: Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med 84: 570-573, 1953.
32. Stewart PL, Burnett RM, Cyrlaff M, Fuller SD: Image reconstruction reveals the complex molecular organization of adenovirus. Cell 67: 145-154, 1991.
33. Stewart PL, Fuller SD, Burnett RM: Difference imaging of adenovirus: bridging the resolution gap between X-ray crystallography and electron microscopy. EMBO J 12: 2589-2599, 1993.
34. Ballay A, Levrero M, Buendia MA, Tiollais P, Perricaudet M: In vitro and in vivo synthesis of the hepatitis B virus surface antigen and of the receptor for polymerized human serum albumin from recombinant human adenoviruses. EMBO J 4: 3861-3865, 1985.
35. Karlsson S, Van Doren K, Schweiger SG, Nienhuis AW, Gluzman Y: Stable gene transfer and tissue-specific expression of a human globin gene using adenoviral vectors. EMBO J 5: 2377-2385, 1985.
36. Yamada M, Lewis JA, Grodzicker T: Overproduction of the protein product of a nonselected foreign gene carried by an adenovirus vector. Proc Natl Acad Sci USA 82: 3597-3571, 1985.
37. Stratford-Perricaudet LD, Levrero M, Chasse JF, Perricaudet M, Briand P: Evaluation of the transfer and expression in mice of an enzyme encoding gene using a human adenovirus vector. Hum Gene Ther 1: 241-256, 1990.
38. Lemarchand P, Jaffe HA, Danel C, Cid MC, Kleinman HK, Stratford-Perricaudet LD, Perricaudet M, Pavirani A, Lecocq J-P, Crystal RG: Adenovirus-mediated transfer of a recombinant human alpha 1-antitrypsin cDNA to human endothelial cells. Proc Natl Acad Sci USA 89: 6482-6486, 1992.
39. Rosenfeld MA, Yoshimura K, Trapnell BC, Yoneyama K, Rosenthal ER, Dalemens W, Fukayama M, Bargon J, Stier LE, Stratford-Perricaudet LD, Perricaudet M, Guggino WB, Pavirani A, Lecocq J-P, Crystal RG: In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68: 143-155, 1992.
40. Glorioso JC, De Luca NA, Fink DJ: Development and application of herpes simplex virus vectors for human gene therapy. Annu Rev Microbiol 49: 675-710, 1995.
41. Thierry AR, Dritschilo A: Intracellular availability of unmodified, phosphorothioates and liposomal encapsulated oligodeoxynucleotides for antisense activity. Nucleic Acids Res 20: 5691-5698, 1992.
42. Bennet CF, Chiang MY, Chan H, Shoemaker JEE, Mirabelli C: Cationic lipids enhance cellular uptake and activity of phosphothioate antisense oligonucleotides. Mol Pharmacol 41: 1023-1033, 1992.
43. Ropert C, Malvy C, Couvreur P: Inhibition of the Friend retrovirus by antisense oligonucleotides encapsulated in liposomes: mechanism of action. Pharm Res 10: 1427-1433, 1993.
44. Thierry AR, Rahman A, Dritschilo A: Overcoming multidrug resistance in human tumor cells using free and liposomally encapsulated antisense oligodeoxynuclcotides. Biochem Biophys Res Commun 190: 952-960, 1993.
45. Ryser HP, Shen WC: Conjugation of methotrexate to poly(L-lysine) increases drug transport and overcomes drug resistance in cultured cells. Proc Natl Acad Sci USA 75: 3867-3870, 1978.
46. Bayard B, Bisbal C, Lebleu B: Activation of ribonuclease L by (2'-5') (A)4-poly(L-lisine) conjugates in intact cells. Biochemistry 25: 3730-3736, 1986.
47. Naldini L, Blomer U, Gallat P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science Z72: 263-267, 1996.
48. Naldini L, Blomer U, Gage FH, Trono D, Verma IM: Efficient gene transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 93: 11382-11388, 1996.
49. Poeschla E, Corbeau P, Wong-Staal F: Development of HIV vectors for anti-HIV gene therapy. Proc Natl Acad Sci USA 93: 11395-11399, 1996.
50. Srinivasakumar N, Chazal N, Prasad CH-MS, Hammarskjold M-L, Rekosh D: The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines. J Virol 71: 5841-5848, 1997.
51. Mocarski ES, Kemble GW, Lyle JM, Greaves RF: A deletion mutant in the human cytomegalovirus gene encoding IEI491aa is replication defective due to a failure in autoregulation. Proc Natl Acad Sci USA 93: 11321-11326, 1996.
52. Robertson ES, Ooka T, Kieff ED: Epstein-Barr virus vectors for gene delivery to B lymphocytes. Proc Natl Acad Sci USA 93: 11334-11340, 1996.
53. Moss B: Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci USA 93: 11341-11348, 1996.
54. Paoletti E: Applications of pox virus vectors to vaccination: An update. Proc Natl Acad Sci USA 93: 11349-11353, 1996.
55. Palese P, Zheng H, Engelhardt OG, Pleschka S, Garcia-Sastre A: Negative-strand RNA viruses: Genetic engineering and applications. Proc Natl Acad Sci USA 93: 11354-11358, 1996.
56. Frolov I, Hoffman TA, Pragai BM, Dryga SA, Huang HV, Schlesinger S, Rice CM: Alphavirus-based expression vectors: Strategies and applications. Proc Natl Acad Sci USA 93: 11371-11377, 1996.
57. Duboise SM, Guo J, Desrosiers RC, Jung JU: Use of virion DNA as a cloning vector for the construction of mutant and recombinant herpsviruses. Proc Natl Acad Sci USA 93: 11389-11394, 1996.
58. Genetic engineering of viruses and of virus vectors. Meeting organized by Bernard Roizman and Peter Palese (Co-chairs), June 9- 11, 1996, National Academy of Sciences in Irvine, California, USA.
59. Shinnick TM, Lerner RA, Sutcliffe JG: Nucleotide sequence of Moloney murine leukemia virus. Nature 293: 543-548, 1981.
60. Takeuchi Y, Cosset FL, Lackmann PJ, Okada H, Weiss RA, Collins MK: Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol 68: 8001-8007, 1994.
61. Landau NR, Littman DR: Packaging system for rapid production of murine leukemia virus vectors with variable tropism. J Virol 66: 5110-5113, 1992.
62. Pear WS, Nolan GP, Scott ML, Baltimore D: Production of helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 90: 8392-8396, 1993.
63. Finer MH, Dull TJ, Qin L, Parson D, Roberts MR: kat: a high-efficiency retroviral transduction system for primary human T lymphocytes. Blood 83: 43-50, 1994.
64. Soneoka Y, Cannon PM, Ramsdale EE, Griffiths JC, Romano G, Kingsman SM, Kingsman AJ: A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res 23: 628-633, 1995.
65. Burns JC, Friedman T, Driever W, Burrascano M, Yee J-K: Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian cells. Proc Natl Acad Sci USA 90: 8033-8037, 1993.
66. Yee J-K, Miyanohara A, LaPorte P, Bouic K, Burns JC, Friedmann T: A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc Natl Acad Sci USA 91: 9564-9568, 1994.
67. Young JAT, Bates P, Willert K, Varmus HE: Efficient incorporation of human CD4 protein into avian leukosis virus particles. Science 250: 1421-1423, 1990.
68. Russell SJ, Hawkins RE, Winter G: Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res 21: 1081-1085, 1993.
69. Kasahara K, Dozy AM, Kan YW: Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 266: 1373-1376, 1994.
70. Chu T-HT, Dornburg R: Retroviral vector particles displaying the antigen-binding site of an antibody enable cell-type-specific gene transfer. J Virol 69: 2659-2663, 1995.
71. Han X, Kasahara N, Kan YW: Ligand-directed retroviral targeting of human breast cancer cells. Proc Natl Acad Sci USA 92: 9747-9751, 1995.
72. Matano T, Odawara T, Iwamoto A, Yoshikura H: Targeted infection of a retrovirus bearing a CD4-Env chimera into human cells expressing human immunodeficiency virus type 1. J Gen Virol 76: 3165-3169, 1995.
73. Chu TH, Dornburg R: Toward highly efficient cell-type-specific gene transfer with retroviral vectors displaying single-chain antibodies. J Virol 71: 720-725, 1997.
74. Valsesia-Wittman S, Drynda A, Deleage G, Aumailley M, Heard J-M, Danos O, Verdier G, Cosset F-L: Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors. J Virol 68: 4609-4619, 1994.
75. Miller DG, Adam MA, Miller AD: Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Molc Cell Biol 10: 4239-4242, 1990.
76. Weinberg JB, Matthews TJ, Cullen BR, Malim MH: Productive human immunodeficiency virus type 1 (HIV-1) infection of nonproliferating human monocytes. J Exp Med 174: 1477-1482, 1991.
77. Lewis P, Hensel M, Emerman M: Human immunodeficiency virus infection of cells arrested in the cell cycle. EMBO J 11: 3053-3058, 1992.
78. Bukrinsky MI, Haggerty S, Dempsey MP, Shanova N, Adzhubel A, Spitz L, Lewis P, Goldfarb D, Emerman M, Stevenson M: A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 365: 666-669, 1993.
79. Blomer U, Naldini L, Kafri T, Trono D, Verma IM, Gage FH: Highly efficient and substained gene transfer in adult neurons with a lentivirus vector. J Virol 71: 6641-6649, 1997.
80. Enders JF, Bell JA, Dingle JH, et al: "Adenoviruses" group name proposed for new respiratory tract viruses. Science 124: 119-120, 1956.
81. Zabner J, Couture LA, Gregory RJ, Graham SM, Smith AE, Welsh MJ: Adenovirus-mediated gene transfer transiently corrects the chlorine transport defect in nasal epithelia of patients with CF. Cell 75: 207-216, 1993.
82. Crystal RG, McElvaney NG, Rosenfeld MA, Chu CS, Mastrangeli A, Hay JG, Brody SL, Jaffe HA, Eissa NT, Danel C: Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 8: 42-51, 1994.
83. Caruso M, Pham-Nguyen K, Kwong Y-L, Xu B, Kosai K-I, Finegold M, Woo SLC, Chen S-H: Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA 93: 11302-11306, 1996.
84. Hermens WT, Giger RJ, Holtmaat AJ, Dijkhuizen PA, Houweling DA, Verhaagen J: Transient gene transfer to neurons and glia: analysis of adenoviral vector performance in the CNS and PNS. J Neurosci Methods 71: 85-98, 1997.
85. van Esseveldt KE, Liu R, Hermens WT, Verhaagen J, Boer GJ: Adenoviral vector-mediated gene transfer and neurotransplantation: possibilities and limitations in grafting of the fetal rat suprachiasmatic nucleus. J Neurosci Methods 71: 113-123, 1997.
86. Liu G, Excoffon KJ, Benoit P, Ginzinger DG, Miao L, Ehrenborg E, Duverger N, Denefle PP, Hayden MR, Lewis ME: Efficient adenovirus-mediated ectopic gene expression of human lipoprotein lipase in human hepatic (HepG2) cells. Hum Gene Ther 8: 205-214, 1997.
87. Pierzchalski P, Reiss K, Cheng W, Cirielli C, Kajstura J, Nitahara JA, Rizk M, Capogrossi MC, Anversa P: p53 induces myocyte apoptosis ria the activation of the renin-angiotensin system. Exp Cell Res 234: 57-65, 1997.
88. Yei S, Mittereder N, Tang K, O'Sullivan C, Trapnel BC: Adenovirus-mediated gene transfer for cystic fibrisis: quantitative evaluation of repeated in vivo vector administration to the lung. Gene Ther 1: 192-200, 1994.
89. Engelhardt JF, Ye X, Doranz B, Wilson JM: Ablation of E2A in recombinant adenovirus improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 91: 6196-6200, 1994.
90. Yang Y, Nunes FA, Berencsi K, Gonczol E, Engelhardt JF, Wilson JM: Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat Genet 7: 362-369, 1994.
91. Yeh P, Dedieu JF, Orsini C, Vigne E, Denefle P, Perricaudet M: Efficient dual transcomplementation of adenovirus E1 and E4 regions from a 293-derived cell line expressing a minimal E4 functional unit. J Virol 70: 559-565, 1996.
92. Dedieu JF, Vigne E, Torrent C, Jullien C, Mahfouz I, Caillaud JM, Aubailly N, Orsini C, Guillaume JM, Opolon P, Delaere P, Perricaudet M, Yeh P: Long-term gene delivery into the livers of immunocompetent mice with E1/E4-defective adenoviruses. J Virol 71: 4626-4637, 1997.
93. Vilquin JT, Guerette B, Kinoshita I, Roy B, Goulet M, Gravel C, Roy R, Tremblay JP: FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. Hum Gene Ther 6: 1391-1401, 1995.
94. Kass-Eisler A, Leinwand L, Gall J, Bloom B, Falck-Pedersen E: Circumventing the immune response to adenovirus-mediated gene therapy. Gene Ther 3: 154-162, 1996.
95. Gall J, Kass-Eisler A, Leinwand L, Falck-Pedersen E: Adenovirus type 5 and type 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J Virol 70: 2116-2123, 1996.
96. Linden RM, Ward P, Giraud C, Winocour E, Berns KI: Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 93: 11288-11294, 1996.
97. Balague C, Kalla M, Zhang WW: Adeno-associated virus Rep78 protein and terminal repeats enhance integration of DNA sequences into the cellular genome. J Virol 71: 3299-3306, 1997.
98. Dong JY, Fan PD, Frizzell RA: Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther 7: 2101-2112, 1996.
99. Buller RM, Janik JE, Sebring ED, Rose JA: Herpes simplex virus type 1 and 2 completely help adenovirus-associated virus replication. J Virol 40: 241-247, 1981.
100. Hoggan MD, Blacklow NR, Rowe, WP: Studies of small DNA viruses found in various adenovirus preparations: physical biological, and immunological characteristics. Proc Natl Acad Sci USA 55: 1467-1474, 1966.
101. Weindler FW, Heilbronn R: A subset of herpes simplex virus replication genes provides helper functions for productive adeno-associated virus replication. J Virol 65: 2476-2483, 1991.
102. Zhou SZ, Cooper S, Kang LY, Ruggeri L, Heimfeld S, Srivastava A, Broxmeyer HE: Adeno-associated virus 2-mediated high efficiency gene transfer into immature and mature subsets of hematopoietic progenitor cells in human umbilical cord blood. J Exp Med 179: 1867-1875, 1994.
103. Kaplitt MG, Leone P, Samulski RJ, Xiao X, Pfaff DW, O'Malley KL, During MJ: Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 8: 148-154, 1994.
104. Ali RR, Reichel MB, Thrasher AJ, Levinsky RJ, Kinnon C, Kanuga N, Hunt DM, Bhattacharya SS: Gene transfer into the mouse retina mediated by an adeno-associated viral vector. Hum Mol Genet 5: 591-594, 1996.
105. Xiao X, Li J, Samulski RJ: Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 70: 8098-8108, 1996.
106. Wagner JA, Gardner P: Toward cystic fibrosis gene therapy. Annu Rev Med 48: 203-216, 1997.
107. Roizman B: The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors. Proc Natl Acad Sci USA 93: 11307-11312, 1996.
108. Frenkel N, Jacob RJ, Honess RW, Hayward GS, Locker H, Roizman B: Anatomy of herpes simplex virus DNA. Characterization of defective DNA molecules and biological properties of virus populations containing them. J Virol 16: 153-167, 1975.
109. Kwong AD, Frenkel N: Herpes simplex virus amplicon: effect of size on replication of constructed defective genomes containing eucariotic DNA sequences. J Virol 51: 595-603, 1984.
110. Kwong AD, Frenkel N: The herpes simplex virus amplicon. Efficient expression of a chimeric chicken ovalbumin gene amplified within defective virus genomes. Virology 142: 421-425, 1985.
111. Geller AI, Yu L, Wang Y, Fraefel C: Helper virus-free herpes simplex virus-1 plasmid vectors for gene therapy of Parkinson's disease and other neurological disorders. Exp Neurol 144: 98-102, 1997.
112. Lachman RH, Efstathiou S: Utilization of the herpes simplex virus type 1 latency-associated region to drive stable reporter gene expression in the nervous system. J Virol 71: 3197-3207, 1997.
113. Fink DJ, Poliani PL, Oligino T, Krisky DM, Goins WF, Glorioso JC: Development of an HSV-based vector for the treatment of Parkinson's disease. Exp Neurol 144: 103-121, 1997.
114. Fink DJ, DeLuca NA, Goins WF, Glorioso JC: Gene transfer to neurons using herpes simplex virus-based vectors. Annu Rev Neurosci 19: 265-287, 1997.
115. Oligino T, Poliani PL, Marconi P, Bender MA, Schmidt MC, Fink DJ, Glorioso JC: In vivo transgene activation from an HSV-based gene therapy vector by GAL:vpl6. Gene Ther 3: 892-899, 1996.
116. Brown OA, Santer RM, Shering AF, Larregina AT, Morelli AE, Southgate TD, Castro MG, Lowenstein PR: Gene transfer into enteric neurons of the rat small intestine in organ culture using a replication defective recombinant herpes simplex virus type 1 (HSV1) vector, but not recombinant adenovirus vectors. Gene Ther 4: 331-338, 1997.
117. Yazaki T, Martuza RL, Rabkin SD: Expression of L1 in primary astrocytes via a defective herpes simplex virus vector promotes neurite outgrowth and neural cell migration. Brain Res Mol Brain Res 43: 311-320, 1996.
118. Dilloo D, Rill D, Entwistle C, Boursnell M, Zhong W, Holden W, Holladay M, Inglis S, Brenner M: A novel herpes vector for the high-efficiency transduction of normal and malignant human hematopoietic cells. Blood 89: 119-127, 1997.
119. Andreansky SS, He B, Gillespie GY, Soroceanu L, Markert J, Chou J, Roizman B, Whitley RJ: The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci USA 93: 11313-11318, 1996.
120. Hamouda T, McPhee R, Hsia SC, Read GS, Holland TC, King SR: Inhibition of human immunodeficiency virus replication by the herpes simplex virus virion shutoff protein. J Virol 71: 5521-5527, 1997.
121. Cook ML, Bastone VB, Stevens JG: Evidence that neurons harbor latent herpes simplex virus. Infect Immun 9: 946-951, 1974.
122. McLennan JL, Darby G: Herpes simplex virus latency: the cellular location of virus in dorsal root ganglia and the fate of the infected cell following virus activation. J Gen Virol 72: 233-243, 1980.
123. Deshmane SL, Fraser NW: During latency, herpes simplex virus type 1 DNA is associated with nucleosomes in a chromatin structure. J Virol 63: 943-947, 1989.
124. Efstathiou S, Minson AC, Field HJ, Anderson JR, Wildy P: Detection of herpes simplex virus-specific DNA sequences in latently infected mice and in humans. J Virol 57: 446-455, 1986.
125. Mellerick DM, Fraser NW: Physical state of the latent herpes simplex virus genome in a mouse model system: evidence suggesting an episomial state. Virology 158: 265-275, 1987.
126. Rock DL, Fraser NW: Detection of HSV-1 genome in central nervous system of latently infected mice. Nature 302: 523-525, 1983.
127. Stevens JG, Wagner EK, Devi RG, Cook ML, Feldman LT: RNA complementary to a herpesvirus alpha gene mRNA is prominent in latently infected neurons. Science 235: 1056-1059, 1987.
128. Randazzo BP, Bhat MG, Kesari S, Fraser NW, Brown SM: Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant. J Invest Dermatol 108: 933-937, 1997.
129. Behr JP: Gene transfer with synthetic cationic amphiles: prospects for gene therapy. Bioconjug Chem 5: 382-389, 1994.
130. Behr JP, Demeneix B, Loeffler JP, Perez-Mutul J: Efficient gene transfer into mammalian primary endocrine cells with lipopolyamine-coated DNA. Proc Natl Acad Sci USA 86: 6982-6986, 1989.
131. Feigner PL, Gadek TR, Holm M, Roman R, Chan HW, Wenz M, Northrop JP, Ringold GM, Danielsen M: Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 84: 7413-7417, 1987.
132. Cotten M, Wagner E: Non-viral approaches to gene therapy. Curr Opin Biotechnol 4: 705-710, 1993.
133. Michael SI, Curiel DT: Strategies to achieve targeted gene delivery via the receptor-mediated endocytosis pathway. Gene Ther 1: 223-232, 1994.
134. Perales JC, Ferkol T, Molas M, Hanson RW: An evaluation of receptor-mediated gene transfer using synthetic DNA-ligand complexes. Eur J Biochem 226: 255-266, 1994.
135. Smythe E, Warren G: The mechanism of receptor-mediated endocytosis. Eur J Biochem 202: 689-699, 1991.
136. Caplen NJ, Alton EW, Middleton PG, Dorin JR, Stevenson BJ, Gao X, Durham SR, Jeffrey PK, Hudson ME, Coutelle C: Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med 1: 39-46, 1995.